Ironwood Pharmaceuticals: Sometimes a Blockbuster Isn't Enough

Why is a company with just 530 employees, and a commercial stage drug with estimated annual sales of more than $1 billion cutting R&D staff?

Jan 13, 2014 at 10:36AM

Small biotechnology companies typically risk everything for their first 15 years or so until their first big drugs win approval. Once sales start rolling in, it should be time to invest in the rest of the pipeline. The last thing a long-term investor wants to see is a cut to the R&D department.

Well, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) began marketing its first big drug, Linzess, in the U.S. about fifteen months ago. Analyst estimates vary, but it is likely to reach peak sales of more than $1 billion dollars per year. Sales, general, and administrative costs (SG&A) have risen, but R&D has remained somewhat level.

IRWD Research and Development Expense (Quarterly) Chart

IRWD Research and Development Expense (Quarterly) data by YCharts

Reports of the launch are positive, but Ironwood's earnings are not. As a result, the company is making cuts. According to a recent report in the Boston Business Journal, some of Ironwood's research staff will be cut during the present quarter.

IRWD Chart

IRWD data by YCharts

Lets take a closer look at Ironwood and its Lizness strategy to see if we can explain this head-scratcher.

The opportunity
Bowel disorders are a big business brimming with opportunities. Frost & Sullivan estimates the U.S. market alone is worth more than $4 billion and rising. Between the two main subtypes, irritable bowel syndrome (IBS) and the more severe inflammatory bowel disease (IBD), there is an inverse relationship between the patient pool and the availability of effective therapies.

For IBD patients with Crohn's disease or ulcerative colitis, there is a growing variety of therapies aimed at the source of inflammation. Sufferers of IBS with symptoms of either constipation (IBS-C), diarrhea (IBS-D), or both (IBS-M) represent an enormous untapped market. Reported cases of IBS outnumber IBD by about ten to one, but there is a surprising lack of effective therapies to treat the condition.

The magnitude of unmet need is well illustrated by the rapid increases in Linzess prescriptions. The FDA approved Lizness for the treatment of chronic idiopathic constipation (CIC) and IBS-C in August 2012, and marketing in the US.. began about a month later. Through November 2013, Ironwood Pharmaceuticals and its North American Lizness partner Forest Laboratories (NYSE:FRX) have reported over 500,000 prescriptions. Between the second and third quarters of 2013, that figure rose 42% from 125,000 to 178,000.

Ironwood estimates a whopping 48 million adults in the U.S. suffer from Linzess' approved indications. Roughly 80%, or about 38.4 million, have access to linaclotide through their insurers or government payers. If U.S. prescription counts keep expanding at their current rate, all of those with access will be on the drug about halfway through 2016.

Typical deal

Before you get too excited, now is a good time to take a closer look at the partnerships Ironwood has forged. Typically, biotechs with a promising compound but no source of revenue make agreements with much larger companies during lead or preclinical stages. The larger company takes responsibility for the immense costs of clinical development and post-approval marketing. In return, smaller companies with practically no financial resources, like Ironwood, are relieved of nearly all of risk while collecting milestone payments whenever their compound manages to jump through regulatory hoops.

Should a co-developed compound reach a commercial stage, the smaller company is armed with collected milestone payments and steady royalties. It can can afford to develop new compounds, and market the same compound in regions where it maintained rights. The smaller company earns less from the partnered compound, but risked very little and now has opportunity to try for a repeat.

Raw deal

Ironwood's partnership with Forest Laboratories is not typical. In the U.S., the two are generally splitting both costs and revenue down the middle. Forest also has sole responsibility for the drug's development and commercialization in Canada and Mexico. In the long run, the deal will probably work out quite well for Forest, but Ironwood is now has to resort to post-approval equity and debt offerings.

In the third quarter of 2013, Forest recorded revenue from linaclotide sales of $34.4 million. Ironwood combines all sales and expenses from the Forest partnership and reports the net gain or loss as a single item. So far it has recorded nothing but losses. In the third quarter, the net loss from the Forest partnership was $6.2 million, and I expect further losses over the next several quarters.

More of the same
With losses piling up, it seems Ironwood cannot afford to market linaclotide in regions outside of the U.S. without help. In China, Ironwood has partnered with AstraZeneca (NYSE:AZN). In return for just $25 million upfront and $125 million in commercial milestone payments, Ironwood and AstraZeneca will split all net losses and profits in the region. In Japan, Ironwood sold rights to linaclotide to Astellas Pharma for modest milestone payments and escalating royalties on gross profits beginning in the low-twenties. The company also entered a similar deal in the E.U. with Almirall.

Final thoughts
If you're interested in smaller biotechnology companies, let this example serve as an important lesson. Investing in a company with an approved product, a large market, and facing little competition makes good sense. Before you go jumping in, though, it pays to take a closer look those collaboration agreements.

Ironwood isn't necessarily in trouble. It may even become wildly profitable, though that won't be until far into the future. For now, I don't think watching earnings slide further negative more than a year after the launch of a potential blockbuster is worth the headache. Cuts in R&D don't bode well for the company's long-term prospects either.

Ironwood might be stagnating, but there's more opportunity in biotech
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers